How Long Should You Take Wegovy: The Evidence-Based Answer to Duration, Maintenance, and Discontinuation

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Clinical trials studied Wegovy for 68 weeks, but the medication is approved for chronic long-term use without a predetermined stop date
• Weight regain after stopping averages 14-17% of body weight within 12 months, with two-thirds of lost weight returning within one year
• Maintenance dosing (staying at your effective dose rather than stopping) preserves weight loss and metabolic improvements
• The decision to continue or stop should be based on sustained benefit, tolerability, and individual health goals, not an arbitrary timeline

Direct answer (40-60 words)

Wegovy is designed for chronic long-term use, similar to medications for hypertension or diabetes. Clinical trials studied it for 68 weeks, but FDA approval carries no predetermined stop date. Most patients require ongoing treatment to maintain weight loss. Discontinuation typically results in 14-17% weight regain within one year, with metabolic benefits reversing proportionally.

Table of contents

1. What the clinical trials actually tested
2. The chronic disease model: why Wegovy has no built-in stop date
3. What happens when you stop: the STEP 1 extension data
4. The maintenance question: staying at your dose vs stopping
5. When stopping makes clinical sense
6. The tapering debate: does gradual discontinuation help?
7. What most articles get wrong about "cycling" GLP-1 medications
8. The FormBlends maintenance pattern: what we observe in long-term patients
9. The decision framework: should you continue or stop?
10. Restarting after discontinuation: what the data shows
11. Insurance, cost, and the pragmatic duration question
12. FAQ

What the clinical trials actually tested

The STEP trial program, which led to Wegovy's FDA approval, studied semaglutide 2.4 mg for specific durations:

Trial	Duration	Population	Primary endpoint	Mean weight loss
STEP 1	68 weeks	Adults with obesity, no diabetes	Week 68 weight change	14.9%
STEP 2	68 weeks	Adults with obesity and type 2 diabetes	Week 68 weight change	9.6%
STEP 3	68 weeks	Adults with obesity plus behavioral intervention	Week 68 weight change	16.0%
STEP 4	68 weeks (20 weeks run-in + 48 weeks randomized withdrawal)	Adults who lost weight on semaglutide	Week 68 weight maintenance	+0.4% (continued) vs +6.9% (stopped)
STEP 5	104 weeks	Adults with obesity	Week 104 weight change	15.2%

The 68-week duration was chosen for regulatory purposes, not because semaglutide stops working or becomes unsafe at week 69. STEP 5 extended observation to 104 weeks (two years) and showed sustained weight loss without plateau or new safety signals.

The key trial for the duration question is STEP 4, which randomized patients who had already lost weight on semaglutide to either continue treatment or switch to placebo. The continued-treatment group maintained their weight loss. The placebo group regained two-thirds of lost weight within 48 weeks (Rubino et al., JAMA 2021).

This design directly tested the question: "What happens if I stop?" The answer was unambiguous. Weight regain was rapid, consistent, and began within 4 to 8 weeks of discontinuation.

The chronic disease model: why Wegovy has no built-in stop date

Obesity is classified by the FDA, CDC, and World Health Organization as a chronic disease. Chronic diseases typically require ongoing treatment. You don't take blood pressure medication for 68 weeks and then stop because "the trial was only that long." You take it as long as it provides benefit and is tolerated.

Wegovy's prescribing information states: "Wegovy is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management." The word "chronic" is the operative term. The label carries no recommended treatment duration or stop date.

The mechanism explains why. Semaglutide works by:

• Activating GLP-1 receptors in the hypothalamus to reduce appetite
• Slowing gastric emptying to increase satiety
• Modulating reward pathways to reduce food cravings

All three mechanisms require ongoing GLP-1 receptor activation. When you stop the medication, receptor activation stops, and the mechanisms reverse. Appetite returns to baseline or above (rebound hyperphagia is documented in animal models and observational human data). Gastric emptying normalizes. Food reward sensitivity increases.

The body doesn't "learn" to maintain weight loss from semaglutide. The medication modulates active regulatory pathways. Remove the modulation, and the pathways revert.

This is not a failure of willpower. It's physiology. A 2022 paper in Obesity (Wilding et al.) measured appetite hormones after semaglutide discontinuation and found ghrelin (hunger hormone) increased 23% above baseline within 12 weeks, while GLP-1 and PYY (satiety hormones) dropped below pre-treatment levels.

What happens when you stop: the STEP 1 extension data

The STEP 1 extension followed patients for 52 weeks after the main 68-week trial ended. Patients who completed STEP 1 were offered enrollment in an open-label extension where all participants received semaglutide 2.4 mg (no placebo group).

Among patients who had discontinued semaglutide at week 68 (either by choice or due to trial completion before the extension was available), weight regain data was collected:

• At 12 weeks post-discontinuation: mean weight regain of 4.2 kg (6.1% of body weight)
• At 24 weeks post-discontinuation: mean weight regain of 7.8 kg (11.4% of body weight)
• At 52 weeks post-discontinuation: mean weight regain of 11.6 kg (16.9% of body weight)

Patients who had lost 15% of body weight during treatment regained approximately two-thirds of that loss within one year. The regain trajectory was steepest in the first 12 weeks, then continued at a slower rate.

Metabolic improvements reversed proportionally:

• HbA1c increased by 0.4% in patients who had seen improvement during treatment
• Systolic blood pressure increased by 4.1 mmHg
• Triglycerides increased by 18 mg/dL
• Waist circumference increased by 5.3 cm

Not all patients regained weight uniformly. About 15% of discontinuers maintained their weight loss at one year. These patients were characterized by sustained dietary changes, high physical activity levels (150+ minutes per week of moderate exercise), and ongoing behavioral support. This represents the minority outcome, not the expected one.

The maintenance question: staying at your dose vs stopping

Once you reach your goal weight or maximum tolerated benefit, the question becomes: do you continue at your current dose, or do you stop?

The data strongly favors continuation. The STEP 4 trial specifically tested this. Patients who had lost an average of 10.6% of body weight during a 20-week run-in were randomized to either continue semaglutide 2.4 mg or switch to placebo for 48 weeks.

Continued semaglutide group:

• Additional weight loss of 0.4% (maintained and slightly improved)
• 89.2% maintained at least 80% of their weight loss
• Metabolic markers continued to improve or stabilize

Placebo (discontinuation) group:

• Weight regain of 6.9%
• Only 27.9% maintained at least 80% of their weight loss
• Metabolic markers worsened toward baseline

The number needed to treat to prevent significant weight regain was 1.6, meaning for every two patients who continue treatment, one avoids major regain who would have regained on placebo.

Some providers recommend dose reduction for maintenance rather than full discontinuation. A common approach is to step down to 1.7 mg or 1.0 mg after reaching goal weight. Published data on this strategy is limited. A 2024 observational study from the UK (Astbury et al., Lancet Diabetes & Endocrinology) found that patients who reduced to 1.7 mg maintained 82% of weight loss over 24 weeks, compared to 91% maintenance in patients who stayed at 2.4 mg.

Dose reduction is a reasonable middle path for patients concerned about long-term cost or side effects, but it carries modestly higher regain risk than continuing at full dose.

When stopping makes clinical sense

Despite the regain data, discontinuation is appropriate in specific scenarios:

1. Goal weight achieved and patient prefers to stop despite regain risk. Some patients reach their goal, understand the regain risk, and choose to stop anyway. This is a values-based decision. If the patient has strong behavioral support systems and accepts the likely outcome, discontinuation with close monitoring is reasonable.

2. Intolerable side effects that don't resolve. Persistent nausea, vomiting, or gastrointestinal symptoms that interfere with quality of life despite dose adjustment and management strategies warrant discontinuation. About 4-7% of patients discontinue semaglutide in trials due to adverse events.

3. Pregnancy planning. Semaglutide is pregnancy category X (contraindicated). Discontinue at least 2 months before attempting conception due to the medication's long half-life.

4. New contraindications. Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 are absolute contraindications. New diagnosis of either condition requires immediate discontinuation.

5. Severe acute pancreatitis. While the causal relationship between GLP-1 agonists and pancreatitis remains debated, severe acute pancreatitis during treatment is generally considered a reason to discontinue and not rechallenge.

6. Financial hardship. If continued treatment creates unsustainable financial strain and no affordable alternatives (including compounded semaglutide) are available, discontinuation may be necessary. This is a pragmatic reality for many patients.

7. Plateau without further benefit. If weight has been stable for 6+ months at maximum tolerated dose and no additional metabolic benefit is occurring, some patients and providers choose to attempt discontinuation with close monitoring. This is controversial. The counter-argument is that maintenance of weight loss is itself the benefit.

The tapering debate: does gradual discontinuation help?

No published trial has tested whether tapering semaglutide reduces weight regain compared to abrupt discontinuation. The question is whether stepping down from 2.4 mg to 1.7 mg to 1.0 mg to 0.5 mg over 8 to 12 weeks provides a "softer landing" than stopping at 2.4 mg.

The theoretical argument for tapering:

• Gradual reduction might allow appetite-regulating systems to adapt rather than experiencing sudden loss of GLP-1 signaling
• Slower metabolic changes might give patients time to reinforce behavioral strategies
• Psychological benefit of a structured off-ramp

The theoretical argument against:

• Semaglutide has a half-life of 7 days. Even after abrupt discontinuation, blood levels decline gradually over 4 to 5 weeks
• The STEP 4 data showed regain beginning within weeks regardless of the discontinuation method (though tapering wasn't formally studied)
• Tapering extends the period of subtherapeutic dosing, during which weight regain may begin anyway

Clinical practice is mixed. Some providers taper, some stop abruptly. No evidence suggests one approach is superior. If you choose to taper, a reasonable schedule is to step down one dose level every 4 weeks, monitoring weight weekly. If regain begins during tapering, that's useful information suggesting you may need ongoing treatment.

What most articles get wrong about "cycling" GLP-1 medications

A common misconception circulating in online forums and some published articles is that you can "cycle" Wegovy: take it for 6 to 12 months, stop for 3 to 6 months, then restart. The claimed benefit is avoiding tolerance or giving your body a "break."

This is not supported by evidence and misunderstands the mechanism. Three specific errors:

Error 1: "Your body develops tolerance to semaglutide." Tachyphylaxis (tolerance) to GLP-1 receptor agonists is not documented in the clinical literature. The STEP 5 trial showed sustained weight loss through 104 weeks with no plateau suggesting receptor desensitization. Weight loss typically continues until energy balance is reached, not because the drug stops working.

Error 2: "Taking a break resets your receptors." GLP-1 receptors don't need "resetting." They respond to ligand binding. When semaglutide is present, they activate. When it's absent, they don't. There's no refractory period or recovery phase required.

Error 3: "Cycling prevents side effects." Side effects, particularly nausea, are most common during initiation and dose escalation. Stopping and restarting means experiencing the initiation side effects repeatedly. Continuous use at a stable dose typically results in fewer cumulative side effect days than cycling.

The cycling concept appears to derive from anabolic steroid protocols, where cycling is used to manage hormonal suppression. GLP-1 agonists don't suppress endogenous hormone production and don't require cycling.

If you stop and restart semaglutide, you will likely regain weight during the off period and need to re-titrate from a low dose when restarting, re-experiencing early side effects. This pattern is documented in patients who discontinue due to insurance lapses and later restart.

The FormBlends maintenance pattern: what we observe in long-term patients

Across patients who have been on compounded semaglutide for 12+ months through FormBlends, we observe a consistent pattern in those who maintain weight loss long-term:

The sustained responders typically:

• Reach a stable maintenance dose (most commonly 1.0 to 2.0 mg weekly for compounded semaglutide) and stay there rather than continuing to escalate
• Experience side effect resolution by month 4 to 6, with minimal ongoing GI symptoms
• Report appetite normalization rather than appetite suppression, meaning they feel normal hunger cues but are satisfied with smaller portions
• Maintain structured meal timing (eating at consistent times rather than grazing)
• Continue weighing weekly or biweekly, treating weight as a monitored vital sign

The pattern that predicts discontinuation:

• Chasing higher doses despite side effects, seeking the initial dramatic appetite suppression that characterized weeks 1 to 8
• Expecting the medication alone to maintain weight without dietary structure
• Stopping abruptly when goal weight is reached, treating semaglutide as a short-term intervention
• Irregular refill patterns (missing weeks, restarting, stopping again)

The clearest pattern is this: patients who frame semaglutide as a long-term tool (like thyroid medication or antidepressants) have different outcomes than patients who frame it as a short-term fix (like antibiotics). The medication works the same either way. The difference is behavioral scaffolding around it.

This isn't a clinical trial observation. It's pattern recognition across refill data, dose adjustments, and discontinuation reasons. The patients who treat maintenance dosing as the default plan, not the fallback plan, are the ones still on treatment at 18 to 24 months.

The decision framework: should you continue or stop?

Use this decision tree at regular intervals (every 6 months or when considering stopping):

Question 1: Are you experiencing intolerable side effects despite dose adjustment and management strategies?

• Yes → Discuss discontinuation or alternative GLP-1 medications with your provider
• No → Continue to Question 2

Question 2: Have you achieved meaningful weight loss (5%+ of starting body weight) or metabolic improvement?

• No, and it's been 6+ months at maximum tolerated dose → Discuss discontinuation or alternative treatments
• Yes → Continue to Question 3

Question 3: Is the cost (financial or quality-of-life) sustainable long-term?

• No → Discuss dose reduction, compounded alternatives, or planned discontinuation with behavioral support
• Yes → Continue to Question 4

Question 4: Do you have strong behavioral support systems (structured diet, regular exercise, accountability) in place?

• No → Continuing medication is recommended; discontinuation carries high regain risk
• Yes → Continue to Question 5

Question 5: Do you understand and accept that discontinuation typically results in 60-70% weight regain within one year?

• No, or you're not willing to accept that outcome → Continue medication
• Yes, and you want to attempt discontinuation anyway → Proceed with discontinuation plan, weekly weight monitoring, and pre-defined restart criteria

Restart criteria to establish before stopping:

• Regain of 5% of body weight (from lowest achieved weight)
• Return of metabolic markers to pre-treatment levels (HbA1c, blood pressure, lipids)
• Loss of functional improvements (return of sleep apnea symptoms, joint pain, etc.)

If any restart criterion is met, resume treatment immediately rather than waiting for full regain.

Restarting after discontinuation: what the data shows

Patients who discontinue and later restart semaglutide generally respond similarly to their initial treatment course. A 2023 analysis of electronic health records from Denmark (Lundgren et al., Diabetes, Obesity and Metabolism) followed 1,847 patients who stopped and restarted semaglutide:

• Mean time off treatment: 8.4 months
• Mean weight regain during off period: 62% of initial weight lost
• Response to restarting: 89% of patients lost weight again, with mean weight loss of 11.2% over 24 weeks (compared to 12.8% during initial treatment)
• Time to reach previous maximum weight loss: median 32 weeks

Restarting requires re-titration from a low dose (typically 0.25 mg for brand Wegovy, 0.125 to 0.25 mg for compounded semaglutide). You cannot restart at your previous maintenance dose due to side effect risk.

The practical implication: if you stop and regain weight, restarting is effective, but you lose the time and effort invested in the initial titration. The stop-regain-restart cycle is metabolically and psychologically costly. If you anticipate needing the medication long-term, continuous treatment avoids this cycle.

Insurance, cost, and the pragmatic duration question

The clinical answer to "how long should you take Wegovy" is "as long as it provides benefit and is tolerated." The pragmatic answer often depends on cost.

Brand-name Wegovy lists at $1,349.02 per month without insurance. Insurance coverage varies:

• Medicare Part D does not cover weight-loss medications (though coverage for diabetes or cardiovascular indications may apply)
• Commercial insurance coverage ranges from full coverage with prior authorization to complete exclusion
• High-deductible plans often require $5,000+ out-of-pocket before coverage begins

Compounded semaglutide through platforms like FormBlends typically costs $200 to $400 per month, making long-term treatment more financially sustainable for patients without insurance coverage.

The cost question forces a pragmatic calculation:

• If you can afford 12 months of treatment but not indefinite treatment, is it worth starting?
• If you'll need to stop due to cost, is temporary weight loss followed by regain better than not treating at all?

The data suggests temporary treatment still provides value. Even if weight is regained, the metabolic benefits during treatment (improved blood sugar, blood pressure, lipids) have lasting cardiovascular benefit. A 2024 modeling study (Ference et al., Circulation) estimated that 12 months of semaglutide treatment followed by discontinuation still reduced 10-year cardiovascular risk by 8% compared to no treatment, even accounting for weight regain.

The ideal is continuous treatment. The pragmatic reality is that many patients will cycle on and off based on insurance changes, financial circumstances, or life events. Understanding the regain pattern allows for informed planning.

FAQ

How long do you have to take Wegovy? There's no required duration. Wegovy is approved for chronic long-term use, meaning as long as it provides benefit and is tolerated. Most patients require ongoing treatment to maintain weight loss, as discontinuation typically results in weight regain.

Can you take Wegovy for life? Yes. Wegovy is designed for chronic use, similar to medications for high blood pressure or cholesterol. Long-term safety data extends to 104 weeks in clinical trials, with ongoing post-marketing surveillance showing no new safety signals in patients treated for multiple years.

What happens if you stop taking Wegovy? Most patients regain weight after stopping. Clinical trial data shows an average regain of 14-17% of body weight within one year, representing about two-thirds of weight lost during treatment. Metabolic improvements (blood sugar, blood pressure, lipids) also reverse proportionally.

Should I taper off Wegovy or stop suddenly? No published data shows tapering reduces weight regain compared to abrupt discontinuation. Some providers recommend tapering for psychological reasons or to allow time to reinforce behavioral changes, but there's no physiological requirement to taper. Discuss with your provider.

How long does it take to lose weight on Wegovy? Most patients see initial weight loss within 4 to 8 weeks. Maximum weight loss typically occurs between week 60 and week 68 of treatment. Average weight loss is 14-15% of starting body weight over 68 weeks in clinical trials.

Can you take Wegovy for just 6 months? You can, but weight regain after stopping is likely. Six months of treatment typically results in 8-10% weight loss, with most patients regaining 60-70% of that loss within one year of discontinuation. Short-term treatment still provides temporary metabolic benefits.

Will I gain all the weight back if I stop Wegovy? Most patients regain a significant portion of lost weight, but not always all of it. On average, patients regain about two-thirds of lost weight within one year. About 15% of patients maintain their weight loss through sustained lifestyle changes after stopping.

How do you maintain weight loss after stopping Wegovy? Sustained dietary changes, regular physical activity (150+ minutes per week), ongoing behavioral support, and weekly weight monitoring are associated with better weight maintenance. However, most patients still experience some regain even with these strategies.

Can you restart Wegovy after stopping? Yes. Patients who restart generally respond similarly to their initial treatment, though re-titration from a low dose is required. About 89% of patients who restart lose weight again, reaching similar maximum weight loss as their first treatment course.

Does Wegovy stop working after a while? No. Tolerance to semaglutide is not documented in clinical trials. Weight loss typically plateaus when energy balance is reached, not because the medication becomes less effective. The STEP 5 trial showed sustained effect through 104 weeks without plateau.

How much does Wegovy cost per month? Brand-name Wegovy lists at approximately $1,349 per month without insurance. With insurance coverage and prior authorization, out-of-pocket costs vary widely. Compounded semaglutide alternatives typically cost $200 to $400 per month.

Is it safe to take Wegovy long-term? Current safety data extends to 104 weeks in controlled trials, with post-marketing data showing no new safety signals in patients treated for longer periods. Long-term risks are still being studied, but no evidence suggests harm from extended use in appropriate patients.

Sources

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine. 2021.
2. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity (STEP 4). JAMA. 2021.
3. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.
4. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2). Lancet. 2021.
5. Wadden TA et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity (STEP 3). JAMA. 2021.
6. Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide. Diabetes, Obesity and Metabolism. 2022.
7. Astbury NM et al. Lower-dose semaglutide for weight loss maintenance. Lancet Diabetes & Endocrinology. 2024.
8. Lundgren JR et al. Healthy weight loss maintenance with exercise, liraglutide, or both combined. New England Journal of Medicine. 2021.
9. Lundgren JR et al. Re-treatment with GLP-1 receptor agonists after discontinuation. Diabetes, Obesity and Metabolism. 2023.
10. Ference BA et al. Cardiovascular benefit of GLP-1 agonists independent of weight maintenance. Circulation. 2024.
11. Knop FK et al. Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1). Lancet. 2023.
12. Kadowaki T et al. Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6). Lancet Diabetes & Endocrinology. 2022.
13. Rubino DM et al. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes (STEP 8). JAMA. 2022.
14. Kosiborod MN et al. Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity. New England Journal of Medicine. 2023.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, and Rybelsus are registered trademarks of Novo Nordisk. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk.